Observational studyInternational journal of impotence research2021
Clinical experience with post-orgasmic illness syndrome (POIS) patients-characteristics and possible treatment modality.
Observational study in International journal of impotence research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Data-Driven symptom clustering identifies four potential phenotypes of self-reported postorgasmic illness syndrome: findings from a large Chinese online survey.International journal of impotence research · 2026Article
- Post-orgasmic illness syndrome and its effects on self esteem and relationships: a survey.International journal of impotence research · 2026Article
- Artificial intelligence meets medical rarity: evaluating ChatGPT's responses on post-orgasmic illness syndrome.International journal of impotence research · 2025Article
- Article
- Recognition and practice patterns of sexual medicine experts towards postorgasmic illness syndrome.International journal of impotence research · 2025Article
- Post orgasmic illness syndrome: a review.International journal of impotence research · 2025Review
- Rare but real: clinical insights and take-home messages from the special issue on rare male sexual disorders.International journal of impotence research · 2025Article
- A Role for IgE in Post-Orgasmic Illness Syndrome: Successful Omalizumab Treatment in Absence of Positive Skin Test to Self Semen.The American journal of case reports · 2025Article
- Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report.Journal of medical case reports · 2024Article
- A clinical guide to rare male sexual disorders.Nature reviews. Urology · 2024Review
- Clinical characteristics, allergic response to autologous semen, and desensitization in patients with postorgasmic illness syndrome.Sexual medicine · 2023Article
- Case series: expanding diagnostic markers in postorgasmic illness syndrome.Sexual medicine · 2023Article
- The first Tunisian case of postorgasmic illness syndrome: A case report.Clinical case reports · 2021Article
- Article
- Novel treatment for post-orgasmic illness syndrome: a case report and literature review.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-orgasmic illness syndrome (POIS) is a rare condition that includes a cluster of post-ejaculatory symptoms with debilitating physical and psychological consequences. The prevalence and incidence of POIS remain unknown as well as the pathophysiology of the syndrome, and there are no well-studied recognized treatment modalities. The current retrospective observational study describes a series of 14 highly selected patients who were actively looking for medical help as POIS has a significant effect on patients and their partners. The aim is to increase knowledge about this syndrome and possible treatment modality. According to a standard protocol, patients have been systematically interviewed, had a physical examination, laboratory blood tests, and treatments. Mean age was 34.07 ± 6.65 years. The majority of patients had only one symptom in common-extreme fatigue. The most prevalent complaints were head pressure/heaviness, nose congestion and muscle tension; all patients suffered from more than 1 symptom. POIS started on average within 30 min of ejaculation and lasted for 3.5 days. The patients reported emotional and psychosocial burden of their symptoms, which also influence their partner and relationships. Immunoglobulin-E measurements did not show elevated levels and/or significant increase within 24 h after ejaculation. Silodosin, a highly selective alpha1A-blocker, which actually causes anejaculation, was effective treatment in 57% of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.